CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...
CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...
In recent years, gene therapy and gene editing are growing in prominence. Leading the gene-editing innovation, CRISPR Therapeutics is poised to make history in this space. The latest data for the ...
Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...
Caribou Biosciences Inc. (NASDAQ:CRBU) shares skyrocketed 100% on Monday after the company released promising Phase 1 ...
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders—sickle-cell disease (SCD) and beta ...
BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announce presentation of new data on exa-cel, ...
CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...
In recent years, researchers have used DNA to encode everything from an operating system to malware. Rather than being a technological curiosity, these efforts were serious attempts to take advantage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback